Literature DB >> 34511951

Seroprevalence and Associated Factors of Hepatitis B and C Virus Among Pulmonary Tuberculosis Patients Attending Health Facilities in Gondar Town, Northwest Ethiopia.

Birhanu Getie1, Getnet Ayalew2, Anteneh Amsalu2,3, Getachew Ferede2, Gizachew Yismaw4, Belay Tessema2.   

Abstract

BACKGROUND: Hepatitis B virus (HBV) and hepatitis C virus (HCV) are hepatotropic viruses whose primary replication occurs in the liver. Despite the significant clinical importance of early screening of hepatitis B and C virus infection in decreasing the hepatotoxicity effect of anti-tuberculosis drugs, screening of hepatitis B and C virus among tuberculosis (TB) patients before treatment has not been practiced in Ethiopia. Thus, this study was conducted to determine the seroprevalence and associated factors of HBV and HCV infections among pulmonary TB (PTB) patients attending health facilities in Gondar, Northwest Ethiopia.
METHODS: A cross-sectional study was conducted among 145 bacteriologically confirmed PTB patients from January 1 to May 30, 2019. After obtaining a signed informed consent from each participant, data on socio-demographic, clinical, and associated factors were collected using a structured pre-tested questionnaire. Besides, a blood sample was collected to determine HBsAg and HCV antibodies by enzyme linked immune sorbent assay (ELISA). The data were entered and analyzed using SPSS version 21. A Fisher's exact test was used to see the relationship between dependent and independent variables, and a p-value ≤0.05 was considered as statistically significant.
RESULTS: Out of the 145 PTB patients screened, 5 (3.4%) patients tested positive for HBsAg, yet none of them were found to be positive for anti-HCV. Besides, the proportion of HIV-positive was 12 (8.3%). History of hospital admission (P= 0.005), tattooing (P= 0.009) and dental extraction (P=0.003) were significantly associated with HBsAg.
CONCLUSION: Although anti-HCV antibodies were not detected, the prevalence of HBV was relatively high in tuberculosis patients. This study highlights the need for the introduction of routine screening of viral hepatitis markers for all TB patients before anti-TB treatment for better management of patients. Likewise, further clinical and epidemiological studies are needed.
© 2021 Getie et al.

Entities:  

Keywords:  hepatitis B virus; hepatitis C virus; pulmonary tuberculosis; seroprevalence

Year:  2021        PMID: 34511951      PMCID: PMC8423494          DOI: 10.2147/IDR.S327503

Source DB:  PubMed          Journal:  Infect Drug Resist        ISSN: 1178-6973            Impact factor:   4.003


  30 in total

1.  Efficacy and safety of Efavirenz in HIV patients on Rifampin for tuberculosis.

Authors:  Diana B Pedral-Sampaio; Carmosina R Alves; Eduardo M Netto; Carlos Brites; Adriano S Oliveira; Roberto Badaro
Journal:  Braz J Infect Dis       Date:  2004-09-29       Impact factor: 1.949

2.  Estimates on HCV disease burden worldwide - filling the gaps.

Authors:  H Wedemeyer; G J Dore; J W Ward
Journal:  J Viral Hepat       Date:  2015-01       Impact factor: 3.728

Review 3.  Extrahepatic Manifestations of Hepatitis C: A Meta-analysis of Prevalence, Quality of Life, and Economic Burden.

Authors:  Zobair Younossi; Haesuk Park; Linda Henry; Ayoade Adeyemi; Maria Stepanova
Journal:  Gastroenterology       Date:  2016-02-26       Impact factor: 22.682

4.  Hepatitis C Disease Burden in the United States in the era of oral direct-acting antivirals.

Authors:  Mark S Roberts; Fasiha Kanwal; Jagpreet Chhatwal; Xiaojie Wang; Turgay Ayer; Mina Kabiri; Raymond T Chung; Chin Hur; Julie M Donohue
Journal:  Hepatology       Date:  2016-06-01       Impact factor: 17.425

5.  Seroepidemiology of hepatitis B virus in Addis Ababa, Ethiopia: transmission patterns and vaccine control.

Authors:  A Abebe; D J Nokes; A Dejene; F Enquselassie; T Messele; F T Cutts
Journal:  Epidemiol Infect       Date:  2003-08       Impact factor: 2.451

6.  Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis.

Authors:  Daphne Yee; Chantal Valiquette; Marthe Pelletier; Isabelle Parisien; Isabelle Rocher; Dick Menzies
Journal:  Am J Respir Crit Care Med       Date:  2003-01-31       Impact factor: 21.405

7.  Viral hepatitis prevalence in patients with active and latent tuberculosis.

Authors:  Hesam Ahmadi Nooredinvand; David W Connell; Mahmoud Asgheddi; Mohammed Abdullah; Marie O'Donoghue; Louise Campbell; Melissa I Wickremasinghe; Ajit Lalvani; Onn Min Kon; Shahid A Khan
Journal:  World J Gastroenterol       Date:  2015-08-07       Impact factor: 5.742

8.  Liver Disease Burden of Hepatitis C Virus Infection in Iran and the Potential Impact of Various Treatment Strategies on the Disease Burden.

Authors:  Behzad Hajarizadeh; Devin Razavi-Shearer; Shahin Merat; Seyed Moayed Alavian; Reza Malekzadeh; Homie Razavi
Journal:  Hepat Mon       Date:  2016-06-14       Impact factor: 0.660

9.  Hepatitis C virus co-infection increases the risk of anti-tuberculosis drug-induced hepatotoxicity among patients with pulmonary tuberculosis.

Authors:  Nino Lomtadze; Lali Kupreishvili; Archil Salakaia; Sergo Vashakidze; Lali Sharvadze; Russell R Kempker; Matthew J Magee; Carlos del Rio; Henry M Blumberg
Journal:  PLoS One       Date:  2013-12-19       Impact factor: 3.240

10.  Hepatitis C and not Hepatitis B virus is a risk factor for anti-tuberculosis drug induced liver injury.

Authors:  Wan Soo Kim; Sang Soo Lee; Chang Min Lee; Hong Jun Kim; Chang Yoon Ha; Hyun Jin Kim; Tae Hyo Kim; Woon Tae Jung; Ok Jae Lee; Jeong Woo Hong; Hyun Seon You; Hyun Chin Cho
Journal:  BMC Infect Dis       Date:  2016-02-01       Impact factor: 3.090

View more
  1 in total

1.  Seroprevalence of Hepatitis B Virus, Hepatitis C Virus, Syphilis and Associated Factors Among Female Sex Workers in Gondar Town, Northwest Ethiopia.

Authors:  Mitikie Wondmagegn; Yitayih Wondimeneh; Alem Getaneh; Getnet Ayalew
Journal:  Infect Drug Resist       Date:  2022-10-14       Impact factor: 4.177

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.